IRODALOM:
1. Kopacova M at al: Peutz- Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol. 2009 Nov 21:15(43): 5397-408.
2. E. Tóth: Kapszulás endoszkópia. Magyar Gasztorenterológus Társaság Vándorgyûlés, Tihany, 2009. június. Szóbeli közlés.
3. E. Tóth: Kapszulás endoszkópia. Magyar Gasztorenterológus Társaság v MiroCam Info – www.intromedic.com
4. The Next Generation Capsule Endoscope – Sayaka – www.rfamerica.com
5. C. Quaglia, E. Buselli, et al: An endoscopic capsule robot: a meso-scale engineering case study. Journal
of micromechanics and microengineering. 2009. 19. 105007.1-105007.11.
6. Given Imaging Launches: Next-Generation PillCam COLON 2 at Gastro 2009 Conference (UEGW, London, 2009. oct.
7. J. Deviere: PillCam COLON Capsule Endoscopy Compared to Colonoscopy in Detecton of Colon Polyps and Cancers: Analysis of a Prospective Multicenter European Study. Gastroenterology 2008; 134 (4 suppl.1):A-38.
8. J. Weiss: Koloskopie und CT-Kolografie bei Diagnostik vergleichbar. Gut 2009; 58:241-248.
9. Lakatos P., Horváth H. Cs., et al: A kettõs ballonos endoszkópia szerepe a vékonybélbetegségek
diagnózisában és kezelésében összehasonlítva a kapszulás endoszkópiával.LAM 2009; 19(11): 691-697.
10. A. Riphaus, S. Richter et al: Capsule Endoscopy Interpretation by an Endoscopy Nurse – a Comparative Trial. Z Gastroenterol 2009; 47: 273-276.
11. O. Möschler, et al.: Complications indouble-balloon-entroscopy: results of the German DBE register. Z Gastroenterol. 2008; 46: 266-270.
12. Kovács M., Pák P., et al: The Impact of Capsule Endoscopy on Surgical Results in Patients with Obscure Gastrointerstinal Bleeding. Z Gastroenterol 2009; 47: 424-428.
13. K. Mönkemüller, C. Olano, et al: Small-bowel endoscopy.Endoscopy 2009; 41: 872-877.
14. PA. Akerman, D. Cantero: Sev ere compliactions of spiral enteroscopy in the first 1750 patients.
Gastrointest Endosc 2009; 69:AB127.
15. T. H. Lee, J. O. Kim, et al: An endoscopic analysis of ulcers of small intestine xetected by double balloon enteroscopy. Gastrointest Endosc 2009; 69:AB203.
16. C. Shepela, K. Wilson: Capsule endoscopy in useful in clarifying diagnosis and guiding management when enedoscopy and histology findings are discordant for the diagnosis of Crohn’s disease. Gastrointest Endosc 2009; 69: AB287.
17. C. Petruzziello, P. Naccarato, et al: Diagnostic role of wireless capsule endoscopy in patients with symptoms highly compatible with Crohn’s disease. Gastroenterology 2009; 136:A350.
18. K. Ohtsuka, H. Kashida, et al: The usefulness of carbon dioxide insufflations for single balloon
238 Gastro Update 2010
panenteroscopy. Castrointest Emndosc 2009; 69:AB192.
19. A. Bourreille, A. Ignjatovic, et al: Role of small-bowel endoscopy in IBD: inbntrnational OMED-ECCO consensus. Endoscopy 2009; 41: 618-637
20. P. A. Akerman, D. Agrawal, et al: Spiral enteroscopy: a novel metod of enteroscopy bí using the Endo-Ease Discovery SB overtube and a pediatric colonoscope. Gastrointest Endosc 2009; 69:327-332.
21. A. S. Cheifetz, A. A. Kornbluth, et al: The risk of retention of the capsule endoscope in patients with known or suspected Crohn’s disease. Am J Gastroenterol 2006; 101:2218-2222.
22. G.C. Sturniolo, V. Di Leo, et al: Small bowel exploratuon by wireless capsule endoscopy: rsults from 314 procedures.A J Med 2006; 119: 341-347.
23. V. Uko, O. Atay, et al: Endoscopic deployment of the wireless capsule using a capsule delivery device in pediatric patients: a case series. Endoscopy 2009; 41:380-382.
24. X. Li, H. Chen, et al: Predictive role of capsule endoscopy ont he insertion route of double-balloon enteroscopy. Endoscopy 2009; 41:762-766.
25. A. Van Gossum, M. Munoz-Navas: Capsule Endosciopy versus Colonoscopy for the Detection of Polyps and Cancer. MN. Engl. J. Med. 2009; 361:3.
26. G. Costamagna, C. Spada, et al: Evaluation of Bowel Preparation and Procedure for PilCam Colon Capsule. An Interim Analysis. DDW 2009 abstrakt
27. T. Rokkas, K. Papaxoinis: A Meta-Analysis to Evaluate Results of Colon Capsule Endoscopy Trials. DDW 2009 abstrakt
28. S. S. Huverlin, M. Le Rhun: Wireless Capsule Colonoscopy Compared to Conventional Colonoscopy in Patients At Moderate or Increased Risk for Colorectal Cancer. Interim Analysis of a Prospective Multicenter Study. DDW 2009 abstrakt.
29. A. Pezzoli, N. Fusetti, et al: Multicenter Preliminary experience with “MIROCAM” capsule endoscopy. Diegstive and Liver Disease. Volume 41, Supplement 1, Marc 2009. S155.
30. Rácz I.: Terhesség – Kapszula endoszkópia. Hajdúszoboszló, szóbeli közlés. 2009.
31. Sung Hwan Kim et al: Gastrointestinal Tract Perforation:MDCT Findings according to the Perforation
Sites Korean J Radiol 2009, 10 (1);63-69.
32. Silano M, Vincentini O, De Vincenzi M.: Toxic, immunostimulatory and antagonist gluten peptides in celiac disease. Curr Med Chem. 2009;16(12):1489-98.
33. Mothes T, Uhlig HH, Richter T.: Recent aspects of antibody determination for the diagnosis of coeliac disease Dtsch Med Wochenschr. 2009 Jul;134(30):1525-8.
34. Dickey W.: ‘Coeliac disease: basics and controversies’. Coeliac disease in the twenty-first century. Joint BAPEN and British Society of Gastroenterology Symposium on Proc Nutr Soc. 2009 Aug;68(3):234-41.
35. Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P, Partanen J, Laurila K, Huhtala H, Paasikivi K, Mäki M, Kaukinen K.: Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology. 2009 Mar;136(3):816-23.
36. Rostami K, Villanacci V. Microscopic enteritis: novel prospect in coeliac disease clinical and immuno- histogenesis. Evolution in diagnostic and treatment strategies. Dig Liver Dis. 2009 Apr;41(4):245-52.
37. Gasbarrini G, Miele L, Malandrino N, Grieco A, Addolorato G, Gasbarrini A, Cammarota G, Bonvicini F.:
Celiac disease in the 21st century: issues of under- and over-diagnosis. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):1-7.
38. Romanos J, van Diemen CC, Nolte IM, Trynka G, Zhernakova A, Fu J, Bardella MT, Barisani D,
A vékony- és vastagbél 239
McManus R, van Heel DA, Wijmenga C.: Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. Gastroenterology. 2009 Sep;137(3):834-40, 840.e1-3.
39. Ho-Yen C, Chang F, van der Walt J, Mitchell T, Ciclitira P.: Recent advances in refractory coeliac disease: a review. Histopathology. 2009 Jun;54(7):783-95.
40. Schmidt C, Kasim E, Schlake W, Gerken G, Giese T, Stallmach A.: TNF-alpha antibody treatment in refractory collagenous sprue: report of a case and review of the literature. Z Gastroenterol. 2009 Jun; 47(6):575-8.
41. Pimentel M.: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58.
42. Fan X, Sellin JH.: Review article:Small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther. 2009 May 15;29(10):1069-77.
43. Abu-Shanab A, Quigley EM.: Diagnosis of small intestinal bacterial overgrowth: the challenges persist! Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):77-87.
44. Vucelic B.: Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Dig Dis. 2009;27(3):269-77.
45. Scherr R, Essers J, Hakonarson H, Kugathasan S.: Genetic determinants of pediatric inflammatory bowel disease: is age of onset genetically determined? Dig Dis. 2009;27(3):236-9.
46. Barahona-Garrido J, Hernández-Calleros J, García-Juárez I, Yamamoto-Furusho JK.: Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility. Saudi J Gastroenterol. 2009 Jul-Sep;15(3):208-12.
47. Grimm MC.: New and emerging therapies for inflammatory bowel diseases. Gastroenterol Hepatol. 2009 Oct;24 Suppl 3:S69-74.
48. Pierce ES.: Where are all The Mycobacterium avium subspecies paratuberculosis in patients with Crohn’s disease? PLoS Pathog. 2009 Mar;5(3):e1000234.
49. Beaugerie L, Sokol H, Seksik P.: Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis. 2009;27(3):375-81.
50. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F: CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617-25.
51. Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, Kuhlmann RS, Otterson MF, Emmons J, Knox J, Binion DG.: Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009 Jan;15(1):25-8.
52. Bar-Meir S.: Mild to moderate Crohn’s disease: still room for step-up therapies? Dig Dis. 2009;27(3): 347-50.
53. McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M: Investigators of the CAST Trial. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009 May;52(5):919-27.
54. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE.: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009 Feb;136(2):441-50.
55. Gervaz P. et al:
56. Crosby JA, Catton CN, Davis A, Couture J, O’Sullivan B, Kandel R et al: Malignant gastrointestinal
240 Gastro Update 2010
stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59.
57.* Gold JS., Gönen M., Gutierrez A., Broto JM., Garcia-del-Muro X. et al: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009 Nov;10(11):1045-52. Epub 2009 Sep 28.
58.* Yeh TS, Liu KH, Su MY, Lin CH, Chiu CT, Tseng JH: Laparoscopically assisted bowel surgery in an era of double-balloon enteroscopy: from inside to outside. Surg Endosc. 2009 Apr;23(4):739-44. Epub 2008 Jul 12.
59. Tabrizian P., Nguyen SQ., Divino CM: Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors J Am Coll Sur. 2009 Jan;208(1):80-6 Epub 2008 Oct 31.
60. Crispin A, et al: Process quality and incidence of acute complications in a series of more than 230000 outpatient colonoscopies. Endoscopy. 2009. Dec.
61. Maslekar S, et al: Randomised controlled trial of patient controlled sedation for colonoscopy: Entonox versus modified patient maintained target controlled Propofol. Colorectal Dis. 2009 Jul.
62. Rex DK: Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology 2009. Oct.
63. Toklu S: Comparison of etomidate-remifentanil and propofol-remifentanil sedation in patients scheduled for colonoscopy. Eur J Anaesthesiol 2009. May.
64. Hayee B: Midazolam with meperidine or fentanyl for colonoscopy: results of a randomized trial. Gastroint Endosc. 2009. Mar.
65. Petrini JL: Unsedated colonoscopy: patient characteristics and satisfaction in a community based endoscopy unit. Gastrointest Endosc. 2009. Mar.
66. Hsieh YH: Propofol alona versus propofol in combination with meperidine for sedation during colonoscopy. J Clin Gastroenterol. 2009. Sep.
67. Robertson DJ: Clinical trial: a randomized, study comparing meperidine (pethidine) and fentanyl in adult gastrointestinal endoscopy. Aliment Pharmacol Ther. 2009. Apr.
68. Benchimol EI, Guttmann A, Griffiths AM, et al: Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009;58:1490-1497.
69. Hou JK, El-Serag H, Thirumurthi S: Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009;104:2100-2109.
70. Frenzel F: Uhlig HH Frequency of indeterminate colitis in children and adults with IBD – a meta-analysis. JCC 2009;3:277-281.
71. Singh S, Graff LA, Bernstein CN: Do NSAIDs, antibiotics, infections or stress trigger flares in IBD. Am J Gastroenterol 2009;104:1298-1313.
72. Roifman I, Sun YC, Fedwick JP, et al: Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175-182.
73. Ho GT, Lee HM, Brydon G, et al: Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-678.
74. Losco A, Vigano C, Conte D, et al: Assessing the activity of perianal Crohn-disease: comparison of clinical indices and computer-assisted anal ultrasound. Inflamm Bowel Dis 2009;15:742-749.
75. Seksik P, Nion-Larmuier I, Sokol H, et al: Effect of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis 2009;15:734-741.
A vékony- és vastagbél 241
76. Keljo DJ, Markowitz J, Langton C, et al: Course and treatment of perianal disease in children newly diagnosed with Crohn’s disease. Inflamm Bow Dis 2009;15:383-387.
77. Sachar DB, Lemmer E, Ibrahim C, et al: Recurrence patterns after first resection for stricturing or penetrating Crohn’s disease. Inflamm Bowel Dis 2009;15:1071-1075.
78. Moffat DC, Ilnyckyj A, Bernstein CN: A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol 2009;104: 2517-2523.
79. Jose FA, Garnett EA, Vittinghof E, et al: Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bow Dis 2009;15:63-68.
80. Ananthakrishnan AN, McGinley EL, Binion DG: Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalisations. Inflamm Bowel Dis 2009;15:182-189.
81. Brackmann S, Andersen SN, Aamodt G, et al: Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bow Dis 2009;15::9-16.
82. Söderlund S, Brandt L, Lapidus A, et al: Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-1567.
83. Branco BC, Sachar DB, Heimann TM, et al: Adenocarcinoma following ileal pouch-anal anastomosis for ulcerative colitis: review of 26 cases. Inflamm Bowel Dis 2009;15:295-299.
84. Feagins LA, Kane SV.: Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 2009;104:768-773.
85. Spiegel BMR, H W, Esrailian E, et al: Controversies in ulcerative colitis: a survey comparing decision makingof experts versus community gastroenterologists Clin Gastroenterol Hepatol 2009;7;168-174.
86. Kamm MA, Lichtenstein GR, Sandborn, WJ, et al: Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009;15:1-8.
87. Dignass AU, Bokemeyer B, Adamek H, et al: Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-769.
88. Kane SV, Accortt NA, Magowan S, Brixner D.: Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009;29:855-862.
89. Higgins PDR, Rubin DT, Kaulback K, et al: Systematic review: impact of non-adherense to 5-aminosalicylic acid products on frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29:247-257.
90. Papi C, Aratari A, Trnatore V, et al: Long.-term prevention of postoperative recurrence in Crohn’s disease cannot be affected by mesalazine. JCC 2009;3:109-114.
91. Regieiro M, Schraut W, Baidoo L, et al: Infliximab prevents Crohn’s disease postoperative recurrence after ileal resection. Gastroenterology 2009;136:441-450.
92. Regieiro M, Schraut W, Baidoo L, et al: Infliximab prevents Crohn’s disease postoperative recurrence after ileal resection. Gastroenterology 2009;136:441-450.
93. Ben-Horin S, Margalyt M, Bossuyt P, et al: Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009;7:981-987.
94. Sood A, Midha V, Makharia GK et al: The probiotic preparation, VSL#3 induces remission in patients eith mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-1209.
95. Thia KT, Mahadevan U, Feagan BG, et al: Ciprofloxacin or metronidazol for the treatment of perianal fistula sin patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24.
242 Gastro Update 2010
96. Gisbert JP, Linares PM, McNicholl AG, et al: Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-137.
97. Mantzaris GJ, Christidou A, Sfakianakis M, et al: Azathioprine is superior to budesonide in achieving and maintaining mucosal mealing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis 2009;15:375-382.
98. Andrews JM, Travis SPL, Gibson PR, Gaché C: Systematic review: doses concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009;29:459-469.
99. Hindorf U, Johansson M, Eriksson A, et al: Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.Aliment Pharmacol Ther 2009;29:654-661.
100. Leung Y, Sparrow MP, Schwartz M, Hanauer SB: Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. JCC 2009;3:162-167.
101. Mares WGN, Wong DR, Gilissen LPL, et al: Safe 6-thioguanine therapy of a TPMT deficient Crohn’s disease patient by using therapeutic drug monitoring. JCC 2009;3:128-130.
102. Wahed M, Louis-Auguste JR, Baxter LM, et al: Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30:614-620.
103. Schmidt KJ, Fellermann K, Wellhöner P, et al: Clinical trial: cyclophosphamide pulse therapy – a promising therapeutic alternative in refractory Crohn’s disease. Aliment Pharmacol Ther 2009;29:1230-1239.
104. Beaugerie L, Brousse N, Bouvier AM, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational study. Lancet 2009;374:1627-1625.
105. Siegel CA, Marden SM, Persing SM, et al: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-881.
106. Lichtenstein GR, Diamond RH, Wagner CL et al: Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009:210-226.
107. Pelletier AL, Kalisazan B, Wienckiewicz J, et al: Infliximab treatment for symptomatic Crohn’s disease strictures. Aliment Pharmacol Ther 2009;29:279-285.
108. Sandborn WJ, Rutgeerts P, Feagan BG, et al: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-1260.
109. Russo EA, Harris AW, Campbell S, et al: Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centre sin England Aliment Pharmacol Ther 2009;29:308-314.
110. Gisbert JP, Panes J: Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009;104:760-767.
111. Viola F, Civitelli F, DiNardi G, et al: Efficacy of Adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol 2009;104:2566-2571.
112. Oussalah A, Babouri A, Chevaux J-B, et al: Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single centre experience. Aliment Pharmacol Ther 2009;29:416-423.
113. Ma C, Panaccione R, Heitman SJ. Et al: Systematic review: the short term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009;30:997-986.
114. Shao L-M, Chen M-Y, Cai J-T: Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease. Aliment Pharmacol Ther 2009;29:605-614.
A vékony- és vastagbél 243
115. Marehbian J, Arrighi M, Hass S, et al: Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 2009;104:2524-2533.
116. Colombel JF, Sandborn WJ, Panaccione R, et al: Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel dis. 2009;15:1318-1319.
117. Valentine JF, Fedorak RN, Feagan B, et al: Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009;58:1354-1362.
118. Gisbert JP, Barmejo F, Pajares R, et al: Oral and Intravenous Iron Treatment in Inflammatory Bowel Disease: Hematological Response and Quality of Life Improvement. Inflamm Bowel Dis 2009; 15: 1485-1491.
119. Abreu MT, von Tirpitz C, Hardi R, et al: Extracorporeal photopheresis for the treatment of refractory Crohn’s disease: results o fan open-label pilot study. Inflamm Bowel Dis 2009;15:829-836.
120. Bolin TD, Wong S, Crouch R, et al: Appendicectomy as a therapy for ulcerative colitis. Am J Gastroenterol 2009;104:2476-2482.
121. Gray JR, Leung E, Scales J: Treatment of ulcerative colitis from the patients’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Therapy 2009;29:1114-1120.
122. Stathaki MI, Koukouraki SI, Karkavitsas NS et al: Role of scintigraphy in inflammatory bowel disease World J Gastroenterol 2009 June 14; 15(22): 2693-2700.
123. Oto A, Zhu F, Kulkarni K et al: Evaluation of Diffusion-weighted MR Imaging for Detection of Bowel inlammation in Patients with Cron’s Disease AJR 2009, 192 (5) 1165-
124. SiddikiHA, FidlerJF, FletcherJG: Prospective Comparison of State-of-the-Art MR Enterography and CT Enterography in Small-Bowel Crohn’s Disease AJR, 2009:193; 11.
125. Lawrance IC, Welman CJ, Shipman P et al: Small bowel MRI enteroclysis or follow through: Which is optimal? World J Gastroenterol 2009 November 14; 15(42): 5300-5306.
126. Herfarth H, Grunert M, Kleb F et al: Frequency and Nature of Incidental Extra-Enteric Lesions Found on Magnetic Resonance Enterography (MR-E) in Patients with Inflammatory Bowel Diseases (IBD) PLoS ONE | www.plosone.org 5 April 2009 | Volume 4 | Issue 4 | e4863.
127. Kodaira C, Osawa S, Mochizuki C et al: A case of small bowel adenocarcinoma in a patient with Crohn’s disease detected by PET/CT and double-balloon enteroscopy. World J Gastroenterol 2009 April 14; 15(14): 1774-177.
128. Lawrance JG, Welman CJ, Shipman P et al: Correlation of MRI-determined small bowel Crohn’s disease categories with medical response and surgical pathology. World J Gastroenterol 2009 July 21; 15(27): 3367-3375.
129.* Yehuda Kariv, MD, Feza H Remzi, MD, FACS, Scott A Strong, MD, FACS, Jeffry P: Hammel, MS, Miriam Preen, BSN, RN, Victor W Fazio, MB, MS, FACS. Ileal Pouch Rectal Anastomosis: A Viable Alternative to Permanent Ileostomy in Crohn’s Proctocolitis Patients. J Am Coll Surg. 2009, 208:390-399.
130.* Alessandroni L, Bertolini R, Campanelli A, Capaldi M, Di Castro A, Mencacci R, Natuzzi G, Cecera A, Tersigni R.: Role of anastomotic configuration in ileocoloc resection for Crohn’s disease. Chir Ital. 2009 Jan-Feb, 61(1):23-31.
131. Kare E. Bakkevold: Construction of an ileocolic neosphincter- Nipple valve anastomosis for prevention of postoperative recurrence of Crohn’s disease in the neoterminal ileum after ileocecal or ileocolic resection. A long-term follow-up study. Journal of Crohn’s and Colitis (2009) 3, 183-188.
132. Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR: National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open appraoches.
244 Gastro Update 2010
J Gastrointest Surg. 2009 Jul, 13(7): 1251-9.
133. Bergamaschi R, Haughn C, Reed JF 3rd, Arnaud JP: Laparoscopic intracorporeal ileocolic resection for Crohn’s disease: is it safe? Dis Colon Rectum. 2009 Apr, 52(4): 651-6.
134. Tanaka S, Matsuo K, Sasaki T, Nakano M, Shimura H, Yamashita Y: Clinical outcomes and advantages of laparoscopic surgery for primary Crohn’s disease: are they significant? Hepatogastroenterology. 2009 Mar-Apr, 56(90): 416-20.
135. da Luz Moreira a, Stocchi L, Tan E, Tekkis PP, Fazio VW: Outcomes of Crohn’s disease presenting with abdominopelvic abscess. Dis Colon Rectum. 2009 May, 52(5): 906-12.
136. Klaus Stienecker, Daniel Gleichmann, Ulrike Neumayer, H Joachim Glaser, Carolon Tonus: Long-term results of endoscopic balloon dilatation of lower gastrointestinal tract strictures in Crohn’s disease: A prospective study. World J Gastroenterol 2009 June 7, 15(21): 2623-2627.
137. Rehg KL, Sanchez JE, Krieger BR, Marcet JE: Fecal diversion in perirectal fistulizing Crohn’s disease is an underutilized and potentially temporary means of successful treatment. Am Surg. 2009 Aug, 75(8): 715-8.
138. Ruffolo C, Penninckx F, Van Assche G, Vermeire S, Rutgeerts P, Coremans G, D’Hoore A: Outcome of surgery for rectovaginal fistula due to Crohn’s disease. Br J Surg. 2009 Oct, 96(10): 1190-5.
139. Schwandner O, Fuerst A: Preliminary results on efficacy in closure of transsphincteric and rectovaginal fistulas associated with Crohn’s disease using new biomaterials. Surg Innov. 2009 Jun, 16(2): 162-8.
140. Iesalnieks I, Glass H, Kilger A, Ott C, Klebl F, Agha A, Schlitt HJ, Strauch U: Perianal fistulas in Crohn’s disease: treatment results at an interdisciplinary unit. Chirurg. 2009 Jun, 80(6): 549-58.
141. Watanabe C, Sumioka M, Hiramoto T, et al: Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis.Inflamm Bowel Dis. 2009 Nov;15(11):1663-9.
142. Bojarski C: Malignant transformation in inflammatory bowel disease: prevention, surveillance and treatment – new techniques in endoscopy. Dig Dis. 2009;27(4):571-5. Epub 2009 Nov 4.
143.* Pakarinen MP, Natunen J, Ashorn M, Koivusalo A, Turunen P, Rintala RJ, Kolho KL: Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics. 2009 May, 123(5): 1377-82.
144. Jennifer Holder-Murray, Alessandro Fichera: Anal transition zone in the surgical management of ulcerative colitis. World J Gastroenterol 2009 February 21, 15(7): 769-773.
145. Murrell ZA, Melmed GY, Ippoliti A, Vasiliauskas EA, Dubinsky M, Targan SR, Fleshner PR: A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009 May, 52(5): 872-8.
146. Baljit Singh, Neil Mortensen and Andrew J Shorthouse: Defunctioning ileostomy following restorative proctocolectomy. Controversial Topics in Surgery. Ann R Coll Surg Engl 2008, 90: 541-545.
147. Michael D Kappelman, MD, MPH, Sheryl L. Rifas-Shiman, MPH, Carol Porter, Daniel A. Ollendorf, MPH, Robert S. Sandler, MD, MPH, Joseph A. Galanko, Ph.D., and Jonathan A. Finkelstein, MD, MPH: Direct Health Care Costs of Crohn’s Disease and Ulcerative Colitis in United States Children and Adults. Gastroenterology. 2008 December, 135(6): 1907-1913.
148. C. Ünlü, S.M.M. de Castro, J.B. Tuynman, A.F. Wüst, E.Ph., Steller, B.A. van Wagensveld: Evaluating routine diagnostic imaging in acute appendicitis. International Journal of Surgery. 7 (2009) 451-455.
149.* Haggi Mazeh, M.D., Irene Epelboym, B.A., Jill Reinherz, M.D., Alexander J. Greenstein, M.D., M.P.H., Celia M. Divino, M.D: Tip appendicitis: clinical implications and management. The American Journal of Surgery (2009) 197, 211-215.
A vékony- és vastagbél 245
150. Michael Freeland, M.D., Erin King, M.D., Karen Safcsak, R.N., Rodney Durham, M.D: Diagnosis of appendicitis in pregnancy. The American Journal of Surgery (2009) 198, 753-758.
151. Soni Soumian, Sudeep Thomas, Prasoon P Mohan, Nadia Khan, Zeeshan Khan, Tirumala Raju:
Management of Hinchey II diverticulitis. World J Gastroenterol 2008 December 21, 14(47): 7163-7169.
152.* Karoui M, Champault A, Pautrat K, Valleur P, Cherqui D, Champault G: Laparoscopic peritoneal lavage or primary anastomosis with defunctioning stoma for Hinchey 3 complicated diverticulitis: results of a comparative study. Dis Colon Rectum. 2009 Apr, 52(4): 609-15.
153. Alamili M, Gögenur I, Rosenberg J: Acute complicated diverticulitis managed by laparoscopic lavage. Dis Colon Rectum. 2009 Jul, 52(7): 1345-9.
154. Martinez ME, Baron JA et al: A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology. (2009) 136:832-841.
155. Warnecke M, Engel UH et al: Biopsies of colorectal clinical polyps-emergence of diagnostic information on deeper levels. Pathol Res Pract. (2009) 205:231-240.
Rubio CA, Höög CM et al: Assessing the size of polyp phantoms in tandem colonoscopies. Anticancer Res (2009) 29: 1539-1546.
156. Rubio CA, Höög CM et al: Assessing the size of polyp phantoms in tandem colonoscopies. Anticancer Res (2009) 29: 1539-1546.
157. Buchner AM, et al: Comparison of probe based Confocal Laser Endomicroscopy with Virtual Chromoendoscopy for Classification of Colon Polyps. Gastroenterology. 2009 Nov 9. [Epub ahead of print]
158. Yeung TM, et al: Advances in endoscopic visualisation of colorectal polyps. Colorectal Dis. 2009 Nov 23. [Epub ahead of print]
159. Tribonias G, et al: Comparison of standard versus high-definition, wide-angle colonoscopy for polyp detection: A Randomized Controlled Trial. Colorectal Dis. 2009 Nov 23. [Epub ahead of print]
160. Ignjatovic A, et al: Optical diagnosis of small colorectal polyps at routine colonoscopy (Detect InSpect ChAracterise Resect and Discard; DISCARD trial): a prospective cohort study. Lancet Oncol. 2009 Dec;10(12):1171-8. Epub 2009 Nov 10.
161. Chang CC, et al: Comparative study of conventional colonoscopy, magnifying chromoendoscopy, andmagnifying narrow-band imaging systems in the differential diagnosis of small colonic polyps between trainee and experienced endoscopist. Int J Colorectal Dis. 2009 Dec;24(12):1413-9.
162. Kudo SE, Kashida H, Ikehara N, et al: Diagnosis of colorectal lesions with the magnifying narrow-band imaging system. Gastrointest Endosc. 2009 Sep;70(3):522-31.
163. Kanao H, Tanaka S, Oka S, at al: Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):631-6.
164. NnAdler A, Aschenbeck J, Yenerim T, et al: Narrow-band versus white-light high definition television endoscopic imaging for screening colonoscopy: a prospective randomized trial. Gastroenterology. 2009 Feb;136(2):410-6.e1; quiz 715.
165. NnParra-Blanco A, et al: Validation of Fujinon intelligent chromoendoscopy with high definition endoscopes in colonoscopy.World J Gastroenterol. 2009 Nov 14;15(42):5266-73.
166. Legoux JL, et al: Structural enhancement and video endoscopy: Results of a large prospective comparative study. Gastroenterol Clin Biol. 2009 Dec;33(12):1101-5.
167. Burke CA, et al: A Comparison of High-Definition Versus Conventional Colonoscopes for Polyp Detection. Dig Dis Sci. 2009 Aug 26.
168. Gorgun E, Church J: Flat adenomas of the large bowel: a single endoscopist study. Dis Colon Rectum. 2009 May;52(5):972-7.
246 Gastro Update 2010
169. van den Broek FJ, van Soest EJ, Naber AH, et al: Combining autofluorescence imaging and narrow-band imaging for the differentiation of adenomas from non-neoplastic colonic polyps among experienced and non-experienced endoscopists. Am J Gastroenterol. 2009 Jun;104(6):1498-507.
170. Aihara H, Sumiyama K, Saito S, et al: Numerical analysis of the autofluorescence intensity of neoplastic and non-neoplastic colorectal lesions by using a novel videoendoscopy system. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):726-33.
171. Kozu T, et al: Effect of orally administered bovine lactoferrin on the growth of adenomatouscolorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res (Phila Pa). 2009 Nov; 2(11):975-83.
172. Witt DM, et al: Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost. 2009 Dec;7(12):1982-9.
173. Saini SD, Nayak RS, Kuhn L, et al: Why don’t gastroenterologists follow colon polyp surveillance guidelines?: results of a national survey.J Clin Gastroenterol. 2009 Jul;43(6):554-8.
174. Miller J, Mehta N, Feldman M, et al: Findings on Serial Surveillance Colonoscopy in Patients With Low-risk Polyps on Initial Colonoscopy. J Clin Gastroenterol. 2009 Jul 17. [Epub ahead of print]
175. Pattullo V et al: The suction pseudopolyp technique : a novel method for the removal of small flatnonpolypoid lesions of the colon and rectum. Endoscopy. 2009.Dec: 41 (12): 2032-7.
176. J. Deviere: PillCam COLON Capsule Endoscopy Compared to Colonoscopy in Detecton of Colon Polyps and Cancers: Analysis of a Prospective Multicenter European Study. Gastroenterology 2008; 134 (4 suppl.1):A-38.
177. J. Weiss: Koloskopie und CT-Kolografie bei Diagnostik vergleichbar. Gut 2009; 58:241-248.
178. V. Pantris, J. Haringsma, et al: Colonoscopy perforation rate, mechanisms and outcome: from diagnostic
to therapeutic colonoscopy. Endoscopy 2009; 41: 941-951.
179. R. Eliakim, K. Yassin, et al: Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009; 41:1026-1031.
180. C. Hassan, A. Zullo, et al: Cost effectiveness of capsule endoscopy in screening for colorectal cancer. Endoscopy 2008; 40:414-421.
181. A. Van Gossum, M. M. Navas, et al: Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N. Engl. J. Med 2009; 361:300-301.
182. Pák P., Kovács M., et al: Kapszulás vastagbélvizsgálat – az elsõ hazai tapasztalatok. Orvosképzés. 2009. december – megjelenés alatt
183. A. Van Gossum, M. Munoz-Navas: Capsule Endosciopy versus Colonoscopy for the Detection of Polyps and Cancer. N. Engl. J. Med. 2009; 361:3.
184. G. Costamagna, C. Spada, et al: Evaluation of Bowel Preparation and Procedure for PilCam Colon Capsule. An Interim Analysis. DDW 2009 abstrakt
185. T. Rokkas, K. Papaxoinis: A Meta-Analysis to Evaluate Results of Colon Capsule Endoscopy Trials. DDW 2009 abstrakt
186. S. Huverlin, M. Le Rhun: Wireless Capsule Colonoscopy Compared to Conventional Colonoscopy in Patients At Moderate or Increased Risk for Colorectal Cancer. Interim Analysis of a Prospective Multicenter Study. DDW 2009 abstrakt
187. A. Pezzoli, N. Fusetti, et al: Multicenter Preliminary experience with “MIROCAM” capsule endoscopy. Diegstive and Liver Disease. Volume 41, Supplement 1, Marc 2009. S155.
188. Robbins J, Pickhardt P, Kim D et al: Intrapatien Comparison of Low Dose Techniques at CT Colonography.
A vékony- és vastagbél 247
AJR, 2009: 192 (5); 32
189. Wise, S.*; Pickhardt, P: Positive Predictive Value for Polyps Detected at Screening CT Colonography: Effect of Polyp Size, Morphology, and Diagnostic Confidence
190. Robbins J, Pickhardt P, Kim D: Flat(Nonpolypoid) Lesions at CT Colonography, AJR, 2009: 192 (5); A32.
191. Stuart A. Taylor, John Brittenden, James Lenton et al: Influence of Computer-Aided Detection False-Positives on Reader Performance and Diagnostic Confidence for CT Colonography Am. J. Roentgenol., Jun 2009; 192: 1682-1689.
192. Seong Ho Park, So Yeon Kim, Seung Soo Lee et al: Sensitivity of CT Colonography for Nonpolypoid Colorectal Lesions Interpreted by Human Readers and With Computer-Aided Detection Am. J. Roentgenol., Jul 2009; 193: 70-78.
193. Perry J. Pickhardt, Cesare Hassan, Andrea Laghiet et al: CT Colonography to Screen for Colorectal Cancer and Aortic Aneurysm in the Medicare Population: Cost-Effectiveness Analysis Am. J. Roentgenol., May 2009; 192: 1332-1340.
194. Ronald M. Summers, Jiamin Liu, Jianhua Yao et al: Automated Measurement of Colorectal Polyp Height at CT Colonography: Hyperplastic Polyps Are Flatter Than Adenomatous Polyps Am. J. Roentgenol., Nov 2009; 193: 1305-1310.
195. Bori R, Sejben I et al: Heterogeneity of pT3 colorectal carcinomas according to the depth of invasion. Pathol Ocol Res (2009)15:527-32.
196. Pollheimer MJ, Kornprat P et al: Clinical significance of pT sub-classification in surgical pathology of colorectal cancer Int J Colorectal Dis (2009) Oct 9. [Epub ahead of print]
197. Mekenkamp LJM, van Krieken JHJM et al: Lymph node retrieval in rectal cancer is dependent on many factors – the role of the tumor, teh patient, the surgeon, the radiotherapist, and the pathologist. Am J Surg Pathol (2009) 33:1547-1553.
198. Sprenger T, Rothe H et al: Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens-results from a prospective evaluation with extensive pathological work-up. J Gastrointest Surg (2009) Oct 15. [Epub ahead of print]
199. Shen SS, Haupt BX et al: Number of lymph nodes examined and associated clinicopathologic factors in colorectal carcinoma. Arch Pathol Lab Med (2009) 133:781-786.
200. Royston D, Jackson DG: Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol (2009) 217:608-619.
201. Tsikitis VL, Larson DL, et al: Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. APMIS (2009) 117:730-736.
202. Wang J, Kulaylat M et al: Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer? Cancer Sci (2009) 100:852-858.
203. Sommariva A, Donisi PM et al: Factors affecting false-negative rates on ex vivo sentinel lymph node mapping in colorectal cancer. Eur J Surg Oncol (2009). Doi:10.1016/j.ejso.2009.06.007
204. Wiese D, Saha S et al: A prospective study of false-positive diagnosis of micrometastatic cells int he sentinel lymph nodes in colorectal cancer. Ann Surg Oncol (2009) 16:2166-2169.
205. Park JS, Chang IT et al: Comparison of ex vivo and in vivo injection of blue dye in sentinel lymph node mapping for colorectal cancer. World J Surg (2009) 33:539-546.
206. Nordgard O, Oltedal S et al: The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis (2009) 24:261-268.
248 Gastro Update 2010
207. Bilchik AJ, Stojadinovich A et al: Targeted lymph node evaluation in colorectal cancer: A decade of progress! J Sug Oncol. (2009) 99:273-274.
208. Bogner B, Hegedûs G: Az elasztikus rostfestés jelentõsége a colorectalis carcinomák vascularis invázióinak kialakulása szempontjából. M Onkol (2009) 53:107-113.
209. Zlobec I, Höller S et al: Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. Dis Colon rectum (2009) 52:1114-1121.
210. Valcz G, Krenács T és mtsai: A myofibroblastok szerepe a vastagbél gyulladásos és daganatos folyamataiban. Orv Hetil (2009) 150:597-602.
211. Valcz G, Krenács T és mtsai: A myofibroblastok szerepe a vastagbél gyulladásos és daganatos folyamataiban. Orv Hetil (2009) 150:597-602.
212. Inafuku Y, Furuhata T et al: Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. J Clin Oncol (2009) 27:1814-1821.
213. Ban S, Shimizu M: Muscularis mucosae in desmoplastic stroma formation of early invasive rectal adenocarcinoma. World J Gastroenterol (2009) 15:4976-4979.
214. Mesker WE, Junggeburt JM, Szuhai K et al: The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Ann Surg (2009) 249: 559-563.
215. Laghi L, Bianchi P et al: CD3+ cells at invasive margin deeply invading (pT3-pT4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. (2009) 10:877-84.
216. Zlobec I, Lugli A: Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 15:5898-906.
217. Camus M, Tosolini M et al: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 69:2685-2693.
218. Lugli A, Karamitopoulou E et al: CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a `pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. British J Cancer (2009) 101:1382-1392.
219. Dresden RC, Peters EEM et al: Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol (2009) 35:1071-1077.
220. Valentini V, Aristei C et al: Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). J Radionc (2009) 92: 148-163.
221. Egészségügyi Minisztérium – módszertani levél: A tápcsatornából vett diagnosztikus szövetminták kórszövettani feldolgozásáról (1. módosított változat). Egészségügyi Közlöny (2009) 21: 3433-3449.
222. Quirke P, Steele R et al: Effect of the plane of surgery achived on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. Lancet (2009) 373:821-8.
223. Kim TH, Chang HJ et al: Pathological nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiation Oncology Biol Phys (2009) Sep 30. [Epub ahead of print]
224. Kojima M, Ishii G: Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. Pathol Int (2009) 59:857-862.
225. Kalady MF, Campos-Lobato LD et al: Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg (2009) 250:582-589.
226. Bertagnolli MM, Niedzwiecki D, Compton CC et al: Microsatellite instability predicts improved
A vékony- és vastagbél 249
response to adjuvant therapy with irinotecan, fluorouracil, and leucovorine in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. Anticancer Res (2009) 29:99-106.
227. Cosentino F, et al: Functional evaluation of the Endotics System, a new disposable self-propelled robotic colonoscope: in vitro tests and clinical trial. J Artif Organs. 2009 Oct 21;32(8):517-527.
228. Salama M, et al: Outcomes of endoscopic resection of large colorectal neoplasms: An Australian experience. J Gastroenterol Hepatol. 2009 Sep 27.
229. Luigiano C, et al: Endoscopic mucosal resection for large and giant sessile and flat colorectal polyps: a single center experience with long term follow up. Endoscopy 2009 Oct.
230. Repici A, et al: Endoscopic mucosal resection for early colorectal neoplasia : pathologic basis, procedure and outcomes Dis Colon Rectum 2009 Aug.
231. Rey JF, Lambert R: Second look colonoscopy: indication and requirements Dig. Endosc. 2009 Jul; 21 Suppl 1:S47-9.)
232. Kim HO, Hwang SI, Yoo CH, et al: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol. 2009 Aug 3. [Epub ahead of print]
233. Loffeld RJ, van der Putten AB: The completion rate of colonoscopy in normal daily practise factors associated with failure. Digestion. 2009, 80(4): 267-70.
234. Brenner H et al: Low Risk of Colorectal Cancer and Advanced Adenomas More than 10 Years after Negativ Colonoscopy. Gastroenterology. 2009. Nov 9.
235. Singh H at al: Predictors of Colorectal Cancer After Negative Colonoscopy : A Population-Based Study. Am J Gastroenterol. 2009 Nov 10.
236. Overholt BF et al: Withdrawal Times and Associated Factors in Colonoscopy: A Quality Assurance Multicenter Assesment. J Clin Gastroenterol. 2009 Oct 29.
237. Singh H et al: Predictors of Colorectal Cancer After Negative Colonoscopy : A Population-Based Study. Am J Gastroenterol. 2009 Nov 10.
238. Warren JL, Klabunde CN, Mariotto AB, et al: Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009 Jun 16;150(12):849-57, W152.
239. Tsoi KK, Pau CYY, Wu WKK, et al: Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009;7:682-688.
240. Laiyemo AI, Murphy G, Sansbury LD, et al: Hyperplastic polyps and the risk of adenoma recurrence in the polyp prevention trial. Clin Gastroenterol Hepatol 2009;7:192-197.
241. Pinsky PF, Schoen RE, Weissfeld JE: The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol 2009;7:86-92.
242. Heitman SJ, Ronksley PE, Hilsden RJ, et al: Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1272-1278.
243. Li D, Jin C, McCulloch C, et al: Association of large serrated polyps with synchronous advanced neoplasia. Am J Gastroenterol 2009;104:695-702.
244. Rozen P, Levi Z, Hazazi R, et al: Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 2009;29:450-457.
245. Rozen P, Levi Z, Hazazi R, et al: Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009;29:906-917.
250 Gastro Update 2010
246. Levin TR: It’s time to make organized colorectal cancer screening convenient and easy for patients. Am J Gastroenterol 2009;104:939-941.
247. Sanaka MR, Deepinder F, Thota PN, et al: Adenomas are detected more often in morning than in afternoon colonoscopy. Am J Gastroenterol 2009;104:1659-1664.
248. Rex D, Johnson DA, Anderson JC, et al: American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterology 2009;104:739-750.
249. Boursi B, Halak A, Umansky M, et al: Colonoscopic screening o fan average-risk population for colorectal neoplasia. Endoscopy 2009;41:516-521.
250. Hoff G, Grotmol T, Skovlund E, et al: Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338:1363-1366.
251. Van Gossum A, Navas MM, Fennandez-Urien I, et al: Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009;361:264-270.
252. Sieg A, Friedrich K, Sieg U: Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. Am J Gastroenterol 2009; 104:848-854.
253. Rex D, Johnson DA, Anderson JC, et al: American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterology 2009;104:739-750.
254. Hol L, van Leerdam ME, van Ballegooijen M, et al: Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
255. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302:649-659.
256. Domingues RC, Carneiro MP, Rueda Lopes FC et al: Whole-Body MRI and FDG PET Fused Images for Evaluation of Patients with Cancer. AJR 2009; 192:1012-1020.
257. Barbaro B, Fiorucci C, Tebala C et al: Locally Advanced Rectal Cancer: MR Imaging in Prediction of Response after Preoperative Chemotherapy and Radiation Therapy Radiology, Radiology; 2009 250: 730-739.
258. Kalaitzakis, E. et al.: Clinicians attitudes towards endoscopic ultrasound: A survey of four European countries. Sand J Gastroenterol, 2009; 44, 1: 100-107.
259. Gress FG., Savides, TJ: Endoscopic ultrasonography. 19.: Colorectal EUS – Bhutani, M.J. p. 160-171, Wiley-Blackwell Ed. 2009.
260. Metzger P., Teleky B: A bél onkológiai sebészete. Gastro Update 2009. Magyar Sebészet, 2009; 62, 4: 233-242.
261. Puli SR. et al.: Accuracy of endoscopic ultrasound to diagnose of nodal invasion by rectal cancers: A meta-analysis and systematic review. Annals of Surgical Oncology, 2009; 16, 5: 1255-1265.
262. Zorcolo, R. et al.: Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic findings. Surgical Endoscopy, 2009, 23,6:1384-1389.
263. Acosta-Mondragon, L., Rosenkranz, L., Berg, M, Patel, S: How accurate is endoscopic ultrasound in restaging recítal adenocarcinoma neoadjunvant therapy? Gastrointest Endoscopy, 2009, 69, 5: 250.
264. Mezzi, G. et al: Endoscopic ultrasound and magentic resonance imaging for re-staging rectal cancer after radiotherapy. World J Gastroenterol, 2009; 15, 44: 5563-5567.
265. Baatrup, G. et al: Preoperative staging and treatment options in T1 rectal adenocarcinoma. Acta
A vékony- és vastagbél 251
Oncologica, 2009; 48:328-342.
266. Beer-Gabel, M. et al: A new rectal ultrasonographic method for the staging of rectal cancer. Dis Colon Rectum, 2009; 52, 8: 1475-1480.
267. van den Broek et al: Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study). BMC Surgery 2009, 15, 19.
268. Buresi, MC et al: The use of endoscopic ultrasonography and other imaging modalities in the preoperative staging of rectal villous tumours: a case of overstaging by magnetic resonance imaging. Can J Gastroenterol, 2009; 23, 9: 639-641.
269. Esclapez, P. et al: Prognostic heterogeneity of endosconographic T3 rectal cancer. Dis Colon Rectum, 2009; 52, 4: 685-691.
270. Gleeson, F: Prospective assessment of EUS criteria for lymphadenopathy associated with rectal cancer. Gastrointest Endoscopy, 69, 4: 896-903.
271. Malauf-Filho, F. et al: An evidence-based consensus statement on the role and application of endosonography in clinical practice. Endoscopy, 2009; 41, 11: 979-987.
272. Meyer, JE., David, L., Sherr, MD: When less is more, when less is less: Local excision in early rectal cancer. Gastrointest Cancer Res, 2009; 3, 6: 123-124.
273. Rectal-cancer treatment – Patient version: Stafes if rectal cancer. National Cancer Institute, 2009; 02/ 10.
274. Scherübl, H: Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy,
2009; 41, 2: 162-165.
275. Akahoshi, K. et al: Endoscopic submucosal dissection of a rectal carcinoid tumor using grasping type scissors forceps. World J Gastroenterol 2009; 15, 17: 2162-2165.
276. Leyden J, Winter DC, Clarke E, O’Keane C: Endoscopic ultrasound and EUS-guided FNA in the diagnosis of rectal endometriosis. Ir Med J 2009; 102, 9: 301.
277. Artifon EL, Furuya P, Sakavi P: Diagnosis of endometriosis with EUS. Gastrointest Endoscopy, 2009; 69, 5: 334.
278. Elmunzer, B. et al: EUS in localizing safe alternate access sites for natural orifice transluminal endoscopic surgery: initil experience in porcine model. Gastrointest Endoscopy, 69, 1: 108-114.
279. De Lusong MA., Shah, JN., Soetikno, R., Binmoeler, KF: Treatment of completely obstructed colonic anastomotic stricture by using a prototype forward-array echoendoscope and facilitated by SpyGlass (with videos). Gastrointest Endoscopy, 2008; 68, 5: 988-992.
280. Ziech M, Bersma RF, Stoker: Imaging perianal fistulas. ClinGastroent Hepatol, 7, 10: 1037-1045
281. Poley, JW: Endoscopic ultrasound. Endoscopy, 2009; 41:885-889.
282. Gottlieb K, Coff P, Preiksaitis H, Juviler A, Fern P: Massive hemorrhage in pregnancy caused by a diffuse cavernous hemangioma of the rectum – EUS as imaging modality of choice. Medscape J Med, 2008; 10, 9:206.
283. Jung SW et al: A case report with lymphangiomatosis of the colon. J Korean Med Sci 2010; 25, 1: 155-158.
284. Lee CK et al: Appendiceal intussusception due to a fecalith mimicking a submucosal tumor. Endoscopy,
2009; 41, 3: 248.
285. Uradomo LT, Darwin PE: Evaluation of subepithelial abnormalities of the appendix by endoscopic ultrasound. Diagnostic Th Endoscopy, 2009, 10: 1155-1160.
286. Santoro GA et al: The value of high resolution three-dimensional endorectal ultrasonography on the management of submucosal invasive rectal tumors. Dis Colon Rectum, 2009; 52, 11: 1837-1843.
252 Gastro Update 2010
287.* West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P: Complete Mesocolic Excision With Central Vascular Ligation Produces an Oncologically Superior Specimen Compared With Standard Surgery for Carcinoma of the Colon. J Clin Oncol. 2009 Nov 30. [Epub ahead of print]
288. Georgiou P, Tan E, Gouvas N, Antoniou A, Brown G, Nicholls RJ, Tekkis P: Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol. 2009 Nov;10(11):1053-62. Epub 2009 Sep 18.
289. Cost Clinical Outcomes of Surgical Therapy Study Group (COST): A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059.
290. Color Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ et al: Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 2005; 6: 477-484.
291. CLASSIC – Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM et al: Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365: 1718-1726.
292. Lacy AM: The Long-term Results of a Randomized Clinical Trial of Laparoscopy-assisted Versus Open Surgery for Colon Cancer, Annals of Surgery 248: 1-7, 2008.
293. Faiz O, Warusavitarne J, Bottle A, Tekkis PP, Darzi AW, Kennedy RH: Laparoscopically assisted vs. open elective colonic and rectal resection: a comparison of outcomes in English National Health Service Trusts between 1996 and 2006. Dis Colon Rectum. 2009 Oct;52(10):1695-704.
294. Neudecker J, Klein F, Bittner R, Carus T, Stroux A, Schwenk W: LAPKON II Trialists. Short-term outcomes from a prospective randomized trial comparing laparoscopic and open surgery for colorectal cancer. Br J Surg. 2009 Dec;96(12):1458-67.
295. Poon JT, Law WL: Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol. 2009 Nov;16 (11):3038-47. Epub 2009 Jul 30.
296. Row D, Weiser MR: An update on laparoscopic resection for rectal cancer. Cancer Control. 2010 Jan; 17(1):16-24.
297. Milsom JW, de Oliveira O Jr, Trencheva KI, Pandey S, Lee SW, Sonoda T: Long-term outcomes of patients undergoing curative laparoscopic surgery for mid and low rectal cancer. .Dis Colon Rectum. 2009 Jul;52(7):1215-22.
298. Gouvas N, Tsiaoussis J, Pechlivanides G, Tzortzinis A, Dervenis C, Avgerinos C, Xynos E: Quality of surgery for rectal carcinoma: comparison between open and laparoscopic approaches. Am J Surg. 2009 Nov;198(5):702-8. Epub 2009 Mar 23.
299. Veldkamp R, Gholghesaei M, Bonjer HJ et al: (2004) European Association of Endoscopic Surgery (EAES). Laparoscopic resection of colon cancer: consensus of the European Association of Endoscopic Surgery (EAES). Surg Endosc 18:1163-1185.
300. Poon JT, Law WL, Fan JK, Lo OS: Impact of the standardized medial-to-lateral approach on outcome of laparoscopic colorectal resection. World J Surg. 2009 Oct;33(10):2177-82.
301. Remzi FH, Kirat HT, Geisler DP: Laparoscopic single-port colectomy for sigmoid cancer. Tech Coloproctol. 2009 Dec 2. [Epub ahead of print]
302. Bucher P, Pugin F, Morel P: Single-port access laparoscopic radical left colectomy in humans. Dis Colon Rectum. 2009 Oct;52(10):1797-
303. Chambers W, Bicsak M, Lamparelli M, Dixon A: Single-incision laparoscopic surgery (SILS) in complex colorectal surgery: a technique offering potential and not just cosmesis. Colorectal Dis.. [Epub ahead of print]
A vékony- és vastagbél 253
304. Middleton PF, Sutherland LM, Maddern GJ: Transanal endoscopic microsurgery: a systematic review. Dis Colon Rectum 2005; 48: 270-284.
305.* Bach SP, Hill J, Monson JR, Simson JN, Lane L, Merrie A, Warren B, Mortensen NJ: Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009 Mar;96(3):280-90.
306. Allaix ME, Arezzo A, Caldart M, Festa F, Morino M: Transanal endoscopic microsurgery for rectal neoplasms: experience of 300 consecutive cases. Dis Colon Rectum. 2009 Nov;52(11):1831-6.
307. Koebrugge B, Bosscha K, Ernst MF: Transanal Endoscopic Microsurgery for Local Excision of Rectal Lesions: Is There a Learning Curve? Dig Surg. 2009;26(5):372-377. Epub 2009 Nov 13.
308. Platell C: Transanal endoscopic microsurgery. ANZ J Surg. 2009 Apr;79(4):275-80.
309. Lebedyev A, Tulchinsky H, Rabau M, Klausner JM, Krausz M, Duek SD: Long-term results of local excision for T1 rectal carcinoma: the experience of two colorectal units. Tech Coloproctol. 2009 Sep;13(3):231-6. Epub 2009 Jul 31.
310. Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A: Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum. 2010 Jan;53(1):16-23.
311. Marks JH, Valsdottir EB, DeNittis A, Yarandi SS, Newman DA, Nweze I, Mohiuddin M, Marks GJ:
Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. Surg Endosc. 2009 May;23(5):1081-7. Epub 2009 Mar 5.
312. Guerrieri M, Baldarelli M, de Sanctis A, Campagnacci R, Rimini M, Lezoche E: Treatment of rectal adenomas by transanal endoscopic microsurgery: 15 years’ experience. Surg Endosc. 2009 Jun 30. [Epub ahead of print]
313. van den Broek FJ, de Graaf EJ, Dijkgraaf MG, Reitsma JB, Haringsma J, Timmer R, Weusten BL, Gerhards MF, Consten EC,Schwartz MP, Boom MJ, Derksen EJ, Bijnen AB, Davids PH, Hoff C, van Dullemen HM, Heine GD, van der Linde K, Jansen JM,Mallant-Hent RC, Breumelhof R, Geldof H, Hardwick JC, Doornebosch PG, Depla AC, Ernst MF, van Munster IP, de Hingh IH,Schoon EJ, Bemelman WA, Fockens P, Dekker E: Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study). BMC Surg. 2009 Mar 13;9:4.
314. Kim JS, Cho SY, Min BS, Kim NK: Risk factors for anastomotic leakage after laparoscopic intracorporeal colorectal anastomosis with a double stapling technique. J Am Coll Surg. 2009 Dec;209(6):694-701.
315. Chude GG, Rayate NV, Patris V, Koshariya M, Jagad R, Kawamoto J, Lygidakis NJ: Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1562-7.
316. Fukami Y, Terasaki M, Sakaguchi K, Murata T, Ohkubo M, Nishimae K: Side-to-end anastomosis in a colostomy for acute malignant large-bowel obstruction: side-to-end anastomosis with a colostomy (STEC procedure). Surg Today. 2009;39(3):265-8. Epub 2009 Mar 12.
317. Ortega-Deballon P, Cheynel N, Di-Giacomo G, Hareth R, Facy O, Rat P: Interposition of a gastric pouch between ileum and anus after proctocolectomy: long-term results in 3 patients. Surgery. 2009 May;145 (5):568-72.
318. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27 (19):3109-16.
254 Gastro Update 2010
319. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009 Jul 1;27(19):3117-25.
320. Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F,Becouarn Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A: A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/ FFCD9802). Ann Oncol. 2009 Apr;20(4):674-80.
321. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O’Reilly S, Chu L, Azar CA, Wolmark N: Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009 Jul 10;27(20): 3385-90.
322. Wolmark, G. Yothers, M. J. O’Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O’Reilly, C. J. Allegra: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. N. J Clin Oncol 27:18s, 2009 (suppl; abstr LBA4).
323. Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset, O, Eide TJ, Halvorsen TB, Tveit KM: Norwegian Gastrointestinal Cancer Group, Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009;48(3):368-76.
324. de Gramont A, Hubbard J, Shi Q, O’Connell MJ, Buyse M, Benedetti J, Bot B, O’Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D: Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. J Clin Oncol.Vol 28, No 3 (January 20), 2010: pp. 460-465.
325. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, MazierMA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D: First BEATinvestigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009 Nov;20(11):1842-7.
326. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A: Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70.
327. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP: Effect of bevacizumab in older patients with metastatic colorectal cancer: pooledanalysis of four randomized studies. J Cancer Res Clin Oncol. 2009 Nov 11.
328. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z: A meta-analysis of randomized controlled trials comparing chemotherapy plus mbevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009 Jun;24(6):677-85.
329. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, MainwaringP, Langer B, Young S:
AVIRI Trial investigators. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77(2): 113-9. Erratum in: Oncology. 2009;77(3-4):256. Oncology. 2009;77(2):following 119. Chiara, Silvia
330. Lievre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepere C, Bachet JB: Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 2009 Sep 28;9:347.
A vékony- és vastagbél 255
331. Ghiringhelli F, Guiu B, Chauffert B, Ladoire S: Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. World J Gastroenterol. 2009 Sep 14;15(34):4278-83.
332. M. Peeters, T. Price, Y. Hotko, A. Cervantes, M. Ducreux, T. André, E. Chan, F. Lordick, A. Rong, J. Gansert:
Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 9.
333. J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M.E. Barugel, Y. Humblet, D. Cunningham, M. Wolf, J.L. Gansert: Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 6.
334. C. Kohne, D. Stroiakovski, C. Chang-chien, R. Lim, T. Pintér, G. Bodoky, C. Stroh, I. Celik, P. Rougier, E. Van Cutsem: Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 4068).
335. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):663-71.
336. T. Maughan, R.A. Adams, C.G. Smith, M.T. Seymour, R. Wilson, A.M. Meade, D. Fisher, A. Madi, J. Cheadle, R. Kaplan: Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 4.
337. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 Feb 5;360(6):563-72.
Comment in:
N Engl J Med. 2009 May 14;360(20):2134; author reply 2135-6. N Engl J Med. 2009 Feb 5;360(6):623-5.
N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6. N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6. N Engl J Med. 2009 May 14;360(20):2134-5; author reply 2135-6.
338. Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G,Flesch M, Buyse M, Mineur L, Carola E, Rivera F, Perez-Staub N, Louvet C, deGramont A: FOLFOX in patients with metastatic colorectal cancer and high alkalinephosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol. 2009 Aug;20(8):1383-6.
339. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P,Tournigand C, Louvet C, de Gramont A: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer?The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009 Dec 1;27(34):5727-33. Comment in: J Clin Oncol. 2009 Dec 1;27(34):5677-9.
340. Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G,Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A: Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol. 2009 Jun;20(6):1042-7.
341. Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Llédo G, Adenis A, Faroux R, Rebischung C, Kockler L, Douillard JY: Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.Br J Cancer. 2009 Nov 17.
256 Gastro Update 2010
342. Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A: A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer. 2009 Jun 2;100(11):1720-4.
343. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM: Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009 Apr 20;27(12):1948-55 Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410-1.
344. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27(22):3677-83.
345. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P,Sobrero A, Ychou M; European Colorectal Metastases Treatment Group; SixthInternational Colorectal Liver Metastases Workshop. Collaborators: Carrato A, Chiang JM, De Hemptinne B, Falcone A, Figueras J, Gigo JF, Georgoulias V, Giuliante F, Glynne-Jones R, Köhne CH, Papamichael D, PostonG, Pozzo C, Tabernero J, Wasan H, Wilson R: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009 Jun;20(6):985-92.
346. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, LangH, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T,Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2009 Nov 24.
347. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J: Surgery with curative- intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009 Oct 6;101(7):1033-8.
348. Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R, Neuhaus P: Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery. 2009 Jul;146(1):52-9.
349. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR,Patel D, D’Angelica M:
Conversion to resectability using hepatic artery infusion p lus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009 Jul 20;27(21):3465-71.
350. Tamandl D, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T: Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol. 2009 Oct 1;100(5):364-71.
351. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM,Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009 Mar;249(3):420-5.
352. Benoist S, Nordlinger B: The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90.
353. Kim SY, Kim HJ, Hong YS, Jung KH, Park JW, Choi HS, Oh JH, Park SJ, Kim SH, Nam BH, Chang HJ, Kim DY: Resected colorectal liver metastases: Does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol. 2009 Sep 21;100(8):713-718.
354. W. O. Bechstein, H. Lang, C. Köhne, F. Parisi, H. R. Raab, A. Frilling, R. Konopke, J. Weitz, C. Stroszczynski, G. Folprecht: Resectability and agreement between surgeons: Review of CT and MR scan of the
A vékony- és vastagbél 257
CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol 27:15s, 2009 (suppl; abstr 4091).
355. Angliviel B, Benoist S, Penna C, El Hajjam M, Chagnon S, Julié C, Beauchet A,Rougier P, Nordlinger B:
Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol. 2009 May;16(5):1247-53.
356. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gönen M, Blumgart L,D’Angelica M: Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009 Aug;16(8):2138-46.
357. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D,Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R,Cunningham D, Van Cutsem E, Bosman F: Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer:Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00Trial. J Clin Oncol.Vol 28, No 3 (January 20), 2010: pp. 466-474.
358. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ,Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS: Cancer and Leukemia Group B; North Central Cancer Treatment Group;Canadian Cancer Society Research Institute; Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 1;15(23):7322-9.
359. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A,Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2009 Oct 15.
360. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10;27(11):1814-21.
361. Chang EY, Dorsey PB, Frankhouse J, Lee RG, Walts D, Johnson W, Anadiotis G, Johnson N: Combination of microsatellite instability and lymphocytic infiltrate as aprognostic indicator in colon cancer. Arch Surg. 2009 Jun;144(6):511-5.
362. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P,Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009 Dec 10;27(35):5924-30. Comment in: J Clin Oncol. 2009 Dec 10;27 (35):5866-7.
363. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V,Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 4;101(3):465-72.
364. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G,Barrett JH, Quirke P:
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009 Dec 10;27(35):5931-7. Comment in: J Clin Oncol. 2009 Dec 10;27(35):5866-7.
365. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009 Jan;14(1):22-8.
366. Meriggi F, Di Biasi B, Abeni C, Zaniboni A: Anti-EGFR therapy in colorectal cancer: how to choose the right patient. Curr Drug Targets. 2009 Oct;10(10):1033-40.
258 Gastro Update 2010
367. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF: Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res. 2009 May;29(5):1615-20.
368. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, Vos AH, Nagtegaal ID, Terstappen LW, Punt CJ: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2009 Oct 27.
369. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M,Koelblinger C, Gruenberger B, Gruenberger T: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009 May;35(5):515-20.
370. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B: Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009 Apr;145(4):362-71.
Bege T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, Moureau-Zabotto L, Giovannini M, Gonçalves A, Delpero JR: Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients. Ann Surg Oncol. 2009 Jan 21.
371. Bege T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, Moureau-Zabotto L, Giovannini M, Gonçalves A, Delpero JR: Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients. Ann Surg Oncol. 2009 Jan 21.
372. Hori M, Oto a, Orrin S et al: Diffusion Weighted MR Imaging for the Diagnosis of anal Fistula AJR 2009, 192(5); 65.
373. Horsthuis K, Lavini C, Bipat S et al: Perianal Crohn Disease: Evaluation of Dynamic Contrast-enhanced MR Imaging as an Indicator of Disease Activity Radiology, 2009 251:380-387.
374. Stoker J, van Randen A, Laméris W et al: Imaging Patients with Acute Abdominal Pain Radiology, 2010, 254 (1); 154-61.
375. Yu J, Fulcher A, Cockrell C et al: Accuracy of MDCT Diagnosis of Blunt Bowel and Mesenteric Injury AJR 2009:192 (5);65-68.
